NanoSphere Announces Revised Terms for Private Placement
NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF) announces revised terms for its non-brokered private placement
previously announced on Nov. 16, 2018. The offering will consist of up to 7,500,000 units at a price of $0.30 per unit for gross
proceeds of up to CAD $2,250,000. Each unit will be comprised of a common share and a full purchase warrant exercisable to purchase
a further common share at a price of $0.50 cents for a period of 24 months, subject to accelerated expiry if the Company’s shares
trade at or above $0.75 for 15 consecutive days.
NanoSphere has developed and patented a radically improved delivery system for cannabinoids that allows for precise dosage,
faster onset of therapeutic effects, and exponentially higher bioavailability. The proceeds from the financing will be used to
finance the expansion of the Company’s production and sales activity.
NanoSphere announced on November 8, 2018 the formation of a wholly owned subsidiary, NanoSphere Cannabis International Inc.
(NCI), which is tasked with licensing NanoSphere’s groundbreaking technology in countries outside the United States where medical
and/or recreational cannabis is legal. The Company is also releasing two new product lines, including an intraoral cannabis product
and an intranasal cannabis spray that can replace the need to smoke or vape cannabis. Both have applications in the medical and
recreational cannabis markets.
The Company may pay certain finder fees in connection with the financing, subject to the policies of the Canadian Securities
Exchange. All securities issuances are subject to the approval of the Exchange and will have a 4-month statutory hold period from
the date of issuance.
NanoSphere’s Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous
evaluation process. For more information about NanoSphere’s licensing program, please visit:
https://www.nanospherehealth.com/licensing/
About NanoSphere
NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a
revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for
the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most
important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more
information on NanoSphere, please visit
http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis.
Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with
nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and
intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing.
Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™
is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications
for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit
https://www.evolveformulas.com/. Follow us on
Facebook,
Instagram and
Twitter.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in
this news release which are not purely historical are forward looking statements, including without limitation any statements
concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes
that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking
statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without
limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be
assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from
those indicated in the forward looking statements. Without limitation, these include assumptions, risks and uncertainties inherent
in completing sub-licensing arrangements in the United States, Canada and abroad, product demand, production, competition and
government regulation of the Cannabis industry, any and all of which may have an adverse effect on the Company’s expansion plans,
sales, revenues and its financial results and condition. Readers are advised to rely on their own evaluation of such risks
and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of
the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the
reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result
of new information, future events or otherwise.
Gabrielle Wesseldyk
gabrielle@rosengrouppr.com
212-255-0945
On behalf of the Board
David Sutton, President and COO
Mobile: 720.520.4283
E-mail: dsutton@nanospherehealth.com
Investor Contact:
Victor Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail: vgoncalves@nanospherehealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005475/en/